<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657472</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_EXA_103</org_study_id>
    <nct_id>NCT03657472</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of CJ-30061 in Healthy Male Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Single-dose, 3-period Replicated Crossover Study to Compare the Pharmacokinetics and Safety Following Administration of CJ-30061 Alone and Co-administration of Amlodipine/Valsartan and Atorvastatin in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics and safety after a single dose administration of CJ-30061 and
      co-administration of Exforge® 5/160mg, Lipitor® 20mg in healthy adult volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2016</start_date>
  <completion_date type="Actual">November 9, 2016</completion_date>
  <primary_completion_date type="Actual">October 29, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of amlodipine</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of valsartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of amlodipine</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of valsartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax of amlodipine</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of valsartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of amlodipine</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of valsartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of amlodipine</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of valsartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt of 2-OH atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of 2-OH atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of 2-OH atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of 2-OH atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of 2-OH atorvastatin</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Sequence 1(RTR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2(RRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3(TRR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-30061</intervention_name>
    <description>Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)</description>
    <arm_group_label>Sequence 1(RTR)</arm_group_label>
    <arm_group_label>Sequence 2(RRT)</arm_group_label>
    <arm_group_label>Sequence 3(TRR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exforge® 5/160mg &amp; Lipitor® 20mg</intervention_name>
    <description>Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg</description>
    <arm_group_label>Sequence 1(RTR)</arm_group_label>
    <arm_group_label>Sequence 2(RRT)</arm_group_label>
    <arm_group_label>Sequence 3(TRR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male aged 19 to 55 years at the time of signing informed consent form.

          -  Subject with BMI from 19kg/m^2 to 27kg/m^2

          -  Decided to participate in the study and provided signed informed consent form
             volutarily after receiving explanation of the objectives, contents, and property of
             Investigational products of the study

        Exclusion Criteria:

          -  Subject who had a medical history of severe hepatobiliary, renal, gastrointestinal,
             cardiovascular, respiratory, endocrinological, neuropsychological, hematological,
             musculoskeletal disease.

          -  Subject who fall under the criteria below in laboratory test.

               -  AST/ALT, total bilirubin, GGT, Uric acid &gt; UNL (upper normal limit) x 1.5

               -  CPK &gt; UNL x 2.5

               -  CrCL &lt; 60mL/min

          -  Subject who fall under the criteria below in Blood Pressure test (siSBP &lt;
             100mmHg/siSBP ≥ 150mmHg or siDBP &lt; 70mmHg/siDBP ≥ 100mmHg)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JaeWook Ko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>September 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>September 2, 2018</last_update_submitted>
  <last_update_submitted_qc>September 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

